CB 401 - Cellestia Biotech
Alternative Names: CB-401 - Cellestia BiotechLatest Information Update: 18 Sep 2023
At a glance
- Originator Cellestia Biotech
- Class Small molecules
- Mechanism of Action Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 07 Sep 2023 Cellestia Biotech plans first-in-human trial for Autoimmune diseases within next 12-18 months by December 2024 (Cellestia Biotech website, September 2023)
- 05 Sep 2023 Preclinical trials in Autoimmune disorders in Switzerland (unspecified route) (Cellestia Biotech pipeline, September 2023)